ALRN Aileron Therapeutics Inc.

+0.01  (+2%)
Previous Close 0.58
Open 0.62
Price To Book 0.55
Market Cap 16,408,111
Shares 27,810,358
Volume 240,755
Short Ratio
Av. Daily Volume 298,220

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Noted that development to be discontinued - no pivotal trial.
Peripheral T-cell lymphoma (PTCL)
Phase 1/1b data due 4Q 2019.
ALRN-6924 and Cytarabine (Ara-C)
Acute myeloid leukemia (AML); Myelodysplastic syndrome (MDS)
Phase 2a preliminary data due at ESMO Sept 27-Oct 1, 2019 with final data due 2H 2020.
ALRN-6924 and IBRANCE (palbociclib)
Solid tumors
Phase 1 has been initiated.
ALRN-6924 and Paclitaxel
Breast cancer
Phase 1b/2 trial to commence September 2019 with data due 2Q 2020.
Small Cell Lung Cancer (SCLC)

Latest News

  1. Aileron Therapeutics Reports Second Quarter 2019 Financial Results
  2. Aileron Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
  3. Aileron Therapeutics to Report Second Quarter 2019 Financial Results on August 6, 2019
  4. What Kind Of Shareholders Own Aileron Therapeutics, Inc. (NASDAQ:ALRN)?
  5. Aileron Therapeutics Announces FDA Acceptance of IND for ALRN-6924 as a Myelopreservation Agent in Patients with p53-mutant Cancer Treated with Chemotherapy
  6. Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach
  7. Aileron Therapeutics to Present at the Jefferies 2019 Healthcare Conference
  8. Aileron Therapeutics Reports First Quarter 2019 Financial Results
  9. Aileron Therapeutics to Report First Quarter 2019 Financial Results on May 8
  10. Aileron Therapeutics Completes $26M Private Placement
  11. Aileron Therapeutics Announces Pricing of $26M Private Placement
  12. Aileron Therapeutics Appoints Kathryn Gregory as Chief Business Officer
  13. 4 Healthcare Stocks Looking To Start February Off Strong
  14. Aileron Therapeutics, Inc. (ALRN) Upgraded to Strong Buy: Here's Why
  15. Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers
  16. Could The Aileron Therapeutics, Inc. (NASDAQ:ALRN) Ownership Structure Tell Us Something Useful?
  17. Aileron Presents Interim ALRN-6924 Data from PTCL, MDS, and AML Clinical Trials at the 60th Annual American Society of Hematology Meeting
  18. Aileron Inks Collaboration Deal With Pfizer for Cancer Combo
  19. Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers
  20. Recent Analysis Shows Arcimoto, ADOMANI, Lipocine, Aileron Therapeutics, Allena Pharmaceuticals, and Perma-Fix Environmental Services Market Influences — Renewed Outlook, Key Drivers of Growth